博尔纳乙肝疫苗课件.ppt

* This slide summarises the key features of Hepavax-Gene TF. Overall, the preferential use of Hepavax-Gene TF? is in accordance with European and US trends to remove mercury-containing compounds from vaccines. Selection of a thiomersal-free vaccine is a prudent approach in line with current thinking about the best medical practice for patients. Note that Hepavax-Gene TF? clinical data are in the process of being published. * * 益可欣TM :具有良好的耐受性 要求上报的不良反应事件 (%) 益可欣TM Hepavax Gene? TC 安在时? 局部任何发红肿胀疼痛 30.32.41.028.2 29.82.40.728.8 22.62.10.719.9 全身性 任何  发热 (?38oC) 皮疹 搔痒 不适，疲劳 关节痛 肌痛 25.51.41.40.78.814.65.114.6 25.10.75.11.77.814.63.413.2 24.70.74.11.48.913.04.115.1 Rebedea I et al. 2006 结论：益可欣TM与安在时?具有类似的安全性和耐受性 * 益可欣TM的热稳定性 WHO立场文件：乙肝疫苗具有良好的热稳定性1 45℃下一周 37 ℃下一个月 WHO正在考虑：乙肝疫苗的运输和现场接种时可无需使用冷链1 严禁冰冻！ （1） Out of Cold Chain: Considerations for Hepatitis B Vaccine, Julie Milstien, University of Maryland School of Medicine * 益可欣TM – 小结全球第一个汉逊酵母基因重组乙肝疫苗 更高免疫原性，更高血清保护率 源于优秀的多形汉逊酵母表达系统 Crucell的核心专利技术 完全不含硫柳汞, 卓越的安全性和耐受性 源于先进的生产工艺 WHO认证，全球广泛使用 已在全球90多个国家广泛使用 全球用量最大的乙肝疫苗之一 UNICEF和PAHO采购量最大的乙肝疫苗 选择不含硫柳汞的疫苗！ * CrucellBringing Innovation to Global Health * 益可欣是新一代的基因重组乙肝疫苗，采用了新型的多形汉逊酵母表达系统，具有更高的免疫原性。 1997年，益可欣获WHO认证，已在全球90多个国家注册使用，累计销售超过6亿剂。 * * * 根据2008年4月的最新调查，中国乙肝表面抗原携带率为7.18%，属于中度流行地区 Hepatitis B is a serious infectious disease caused by the hepatitis B virus (HBV). Of the 2 billion people who have been infected with HBV worldwide, over 350 million have chronic infections and are carriers.1 About 1 million chronically infected people die each year from liver cirrhosis or liver cancer.1 Hepatitis B is a serious global public health problem, and is found in many parts of the world. The map shows the number of deaths from hepatitis B in the different World Health Organization (WHO) regions of the world in 2002, and clearly shows the uneven distribution of disease burden.2 {Note that the WHO reports these figures without including